Bernstein Downgrades Novo Nordisk (NVO) to Underperform
More News related to NVO
- Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
- Novo Nordisk A/S -- Treasury Stock
- Medarex (MEDX) Will Receive Milestone Payment from Novartis (NVO) for FDA Approval of Ilaris
- Novo Nordisk Insulin Analogs Have Proven Safety Profiles
- Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
Sanford Bernstein downgrades Novo Nordisk (NYSE: NVO) from Market Perform to Underperform.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
Related Categories
DowngradesStocks Mentioned
-29.88Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
